MDR-TB Treatment & Prevention

Carlos,

Yes, this is very interesting. Send me/us more detail(s) as they come up, also should you/your group need patients for test runs on your research do not hesitate to let me know and partner together as 25% of our group members at Living Hope Organization (Livhorg) have TB.
 
Thank You,

Jude C. Munaonye (CEO)
Living Hope Organization
21, Timber Road
P M B 7215, Abia State , Nigeria.
Phone: +2348035482398, +2348055931405
http://www.bbc.co.uk/sinhala/news/story/2007/08/070823_nigeria_aids.shtml
http://livhorg.blogspot.com/

Dear Jude:

Thanks for your reply. I recommend you to write directly to Dr. Iseu Nunes,
Farmabrasilis CEO, .

With my best wishes,
Carlos

Dear Jude,

Thank you for your interest in Farmabrasilis and P-MAPA.

Farmabrasilis is a non-governmental, non-profit research network
bringing together Brazilian, Chilean, American and European scientists
and people devoted to the research and development of new medicines
and technologies for the benefit of economically disadvantaged
populations and individuals affected by neglected diseases.

The final goal of our organization is to contribute to the fight
against TB, malaria and other infectious diseases, particularly in
developing countries, where the problem is compounded by the spread of
HIV-AIDS. Our medicines, including P-MAPA can be licensed without
royalties in order to allow their use by populations that would
otherwise be unable to purchase them.

In the absence of a vaccine against HIV, immunotherapy may
represent a valuable approach to fighting TB and other infectious
diseases, if used in combination with existing therapies. A candidate
to play this role is the immunomodulator P-MAPA.

Although this compound was originally intended for cancer treatment
and it has been shown to have anti-tumour activity, P-MAPA also
modulates the production of interferon-gamma and interleukin-10, known
to be key substances in the body’s defences against Tuberculosis,
malaria and other infectious diseases.  

Furthermore, extensive studies showed that P-MAPA stimulates human ...

Dear Jude,

Thank you for your interest in Farmabrasilis and P-MAPA.

Farmabrasilis is a non-governmental, non-profit research network
bringing together Brazilian, Chilean, American and European scientists
and people devoted to the research and development of new medicines
and technologies for the benefit of economically disadvantaged
populations and individuals affected by neglected diseases.

The final goal of our organization is to contribute to the fight
against TB, malaria and other infectious diseases, particularly in
developing countries, where the problem is compounded by the spread of
HIV-AIDS. Our medicines, including P-MAPA can be licensed without
royalties in order to allow their use by populations that would
otherwise be unable to purchase them.

In the absence of a vaccine against HIV, immunotherapy may
represent a valuable approach to fighting TB and other infectious
diseases, if used in combination with existing therapies. A candidate
to play this role is the immunomodulator P-MAPA.

Although this compound was originally intended for cancer treatment
and it has been shown to have anti-tumour activity, P-MAPA also
modulates the production of interferon-gamma and interleukin-10, known
to be key substances in the body’s defences against Tuberculosis,
malaria and other infectious diseases.  

Furthermore, extensive studies showed that P-MAPA stimulates human
toll-like receptors, induced proliferation of lymphocyte T, increases
cytokine production (mainly interferon-gamma and interleukin-2), and
NK cell activity and stimulate NO release by macrophages.

This had led Farmabrasilis to put forward a new approach to
treating patients with these conditions - including those co-infected
with HIV - which would involve attempting to re-establish patients’
immunocompetence by adjuvant immunotherapy with P-MAPA.

This proposed therapeutic approach was presented to delegates at
STOP TB Partners Forum, Rio 2009.

The results on Tuberculosis mentioned by Carlos Fioravanti 
supports our proposal.

In case of interest, please see the full text named “The
Farmabrasilis Infected Diseases Proposal” at:  


http://www.farmabrasilis.org.br/pesquisa_desenvolvimento_interna.php?idioma=e...

Farmabrasilis welcomes new partners to help advance this proposal.
We will be glad to discuss different partnership formats to pursue
common goals.

If there are your interests, please let us know or simply write an
e-mail to me: [2]

 Best regards,

Iseu Nunes

Farmabrasilis -CEO

Dear all,

There is need to try P-MAPA in sub-Saharan Africa. No doubt, that it will be a valuable resource to the people as most (up to 70% or more) of the TB patients are co-infected with HIV. I would like to add that a US NIAID research team has confirmed in 2009 markable effects of P-Mapa against other intracellular microbes. The P-MAPA compound acts in vivo against a virus (Punta toro virus) related to the African Rift Valley Fever virus, a cause of great concern in sub-Saharan Africa.Punta Toro virus (PTV) is a member of the Bunyaviridae family related to the highly pathogenic Rift Valley fever virus (RVFV).

In case of interest, please, see bellow the full content of free Abstract published in Antiviral research :

A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus.

“Intracellular pathogens with widespread drug-resistance contribute substantially to the increasing rates in morbidity and mortality due to emerging and reemerging diseases. Thus, the development of new drugs, including those that can enhance the immune response, is urgently needed. The immunomodulator, P-MAPA, a proteinaceous aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride derived from Aspergillus oryzae ...

Dear all,

There is need to try P-MAPA in sub-Saharan Africa. No doubt, that it will be a valuable resource to the people as most (up to 70% or more) of the TB patients are co-infected with HIV. I would like to add that a US NIAID research team has confirmed in 2009 markable effects of P-Mapa against other intracellular microbes. The P-MAPA compound acts in vivo against a virus (Punta toro virus) related to the African Rift Valley Fever virus, a cause of great concern in sub-Saharan Africa.Punta Toro virus (PTV) is a member of the Bunyaviridae family related to the highly pathogenic Rift Valley fever virus (RVFV).

In case of interest, please, see bellow the full content of free Abstract published in Antiviral research :

A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus.

“Intracellular pathogens with widespread drug-resistance contribute substantially to the increasing rates in morbidity and mortality due to emerging and reemerging diseases. Thus, the development of new drugs, including those that can enhance the immune response, is urgently needed. The immunomodulator, P-MAPA, a proteinaceous aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride derived from Aspergillus oryzae, have been shown to induce antitumor activities. The ability of this compound to elicit protective immunity against viral infections has not been fully explored. Here, we report findings on the use of P-MAPA as an antiviral agent in a mouse model of acute phleboviral (Punta Toro virus) disease. A single dose administered i.p. 24 h post-infectious challenge (100 mg/kg dose of P-MAPA) was remarkably effective at preventing death due to Punta Toro virus infection. This dose also reduced systemic viral burden and liver discoloration assayed on day 3 of infection. Taken together, our findings indicate that non-specific immunotherapy with P-MAPA appears to be an effective treatment for blocking Punta Toro virus-induced disease and suggest that further exploration with other viral disease models is warranted "

Antiviral Research- vol.83, Issue 2, August 009, pages 143-147

Best regards,

Pietr

Dear All
I don't know how you can assist in that we manage to know our MDR-TB situation. Should I be afraid to speak out but this is the situation we are in not that we do not have MDR-TB but

Regina Medical Laboratory Scientist